Infinity Pharmaceuticals, Inc. (INFI) Analysts See $-0.17 EPS

October 13, 2018 - By whatsonthorold

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) LogoInvestors sentiment decreased to 1.04 in 2018 Q2. Its down 0.28, from 1.32 in 2018Q1. It dived, as 13 investors sold Infinity Pharmaceuticals, Inc. shares while 12 reduced holdings. 12 funds opened positions while 14 raised stakes. 27.57 million shares or 1.56% more from 27.14 million shares in 2018Q1 were reported.
Grp One Trading Ltd Partnership reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Federated Invsts Pa invested in 0% or 2,308 shares. Cambridge Invest owns 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 22,245 shares. Millennium Mngmt Ltd Liability Corp holds 0% or 110,155 shares in its portfolio. Wells Fargo And Communications Mn invested in 97,789 shares. Essex Invest Mgmt Limited Liability Company holds 0.04% or 164,605 shares. Bvf Il invested in 2.84% or 15.23M shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Manufacturers Life Insur The holds 0% or 2,628 shares in its portfolio. Connor Clark Lunn Invest Ltd has 22,724 shares for 0% of their portfolio. State Street Corp reported 59,605 shares. Clear Harbor Asset Management Limited Liability Company owns 95,630 shares. Bancorporation Of Mellon has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Vanguard Gp, Pennsylvania-based fund reported 2.18 million shares. Community Bank & Trust Na accumulated 14,000 shares.

Since June 19, 2018, it had 1 buying transaction, and 2 insider sales for $6.45 million activity. The insider BVF PARTNERS L P/IL bought 3.94M shares worth $6.50 million.

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $-0.17 EPS on November, 6.They anticipate $0.03 EPS change or 21.43 % from last quarter’s $-0.14 EPS. After having $-0.12 EPS previously, Infinity Pharmaceuticals, Inc.’s analysts see 41.67 % EPS growth. The stock increased 3.02% or $0.07 during the last trading session, reaching $2.39. About 198,402 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has risen 82.50% since October 14, 2017 and is uptrending. It has outperformed by 66.88% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $135.87 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

More important recent Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news were published by: Benzinga.com which released: “45 Biggest Movers From Yesterday” on October 03, 2018, also Seekingalpha.com published article titled: “Infinity Pharma up 7% premarket on $22M milestone from Verastem”, Benzinga.com published: “38 Stocks Moving In Tuesday’s Mid-Day Session” on October 02, 2018. More interesting news about Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) was released by: Benzinga.com and their article: “26 Stocks Moving In Tuesday’s Pre-Market Session” with publication date: October 09, 2018.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>